What is the half-life of Pemvidutide?
Pemvidutide has a reported half life of ~5 days, given subcutaneous. That is why it is typically dosed once weekly. A shorter half life means more frequent dosing to keep blood levels steady, a longer one lets you space doses further apart.
Quick facts
- Half-life: ~5 days
- Route: Subcutaneous
- Typical schedule: Once weekly
- Cycle length: Trial protocols
References
- Pemvidutide for the treatment of NAFLD/NASH, Phase 1b — Altimmune Phase 1b readout, 2023
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study — Harrison SA et al., Journal of Hepatology, 2025
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis — Noureddin M et al., The Lancet, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Pemvidutide
Last updated 2026-06-06.